On Monday, Envista Holdings Corp (NVST) stock saw a modest uptick, ending the day at $21.28 which represents a slight increase of $0.34 or 1.62% from the prior close of $20.94. The stock opened at $21 ...

In a report released on November 1, Jonathan Chang from Leerink Partners reiterated a Buy rating on Molecular Partners (MOLN – Research ...

Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...

To help foot the bill to launch its approved graft-versus-host disease drug Niktimvo and the expected launch of its leukemia treatment revumenib, Syndax has struck a $350 million licensing deal with ...

The results "showed strong cost discipline in the face of a tough operating environment," Leerink Partners analyst Michael Cherny said in a note. The company raised the lower end of its adjusted ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Voyager Therapeutics (VYGR – Research Report), Align Tech ...

Fintel reports that on November 4, 2024, Leerink Partners initiated coverage of Zura Bio (NasdaqCM:ZURA) with a Outperform ...

The news led to a stock surge on expectations that forthcoming data for the company’s experimental gene therapy for Rett ...

Wall Street analysts were impressed by data showing competitive rates of weight loss for Viking’s therapy, but shares in the ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.21% of ...

Viking Therapeutics (VKTX) surges on promising obesity drug results. Explore key price levels and analyst insights in this detailed analysis.

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ®), announced today the ...